Charlie Petty

Entrepreneurial technology investor and operator.

Who I am:

My name is Charlie Petty and I have been a technology investor for the past 10+ years, first in traditional industrial technology leveraged buyout investing and for the past six years in healthcare and life sciences venture capital. I have spent the past 5+ years forming funds and investing on behalf of foundations, corporations, governments, and other mission-driven investors. I have helped raise nearly $800,000,000 in LP commitments across three healthcare impact funds and have helped prosecute 20+ investments and served as a director and observer on nearly a dozen boards.

My next chapter:

We are at a critical inflection point in human history. Both AI and biotechnology have the potential to transform our civilization and I am compelled to drive the positive applications of these technologies and avert their catastrophic misuse. I believe my background in finance, operations, organizational leadership, and governance position me to contribute to the success of companies and/or organizations working on high stakes projects in these spaces.

As a discrete example of where I believe I can contribute: a number of foundations as well as AI labs have limited financial expertise. I have observed a similar gap across organizations in the broader EA and EA-adjacent ecosystem. I believe this significantly

I would be highly interested in working with the leadership teams of these organisations to build teams focused on financial management, fundraising, and, where appropriate, investing in support of their impact focus through the development of program related investments and other similarly rigorous programs.

How you can help:

I am eager to make a change in the next few quarters and would love to speak on an informational basis with founders, leaders, advisors, investors, and grantmakers in these domains for advice and potential opportunities. My default path should I not identify a compatible role as outlined above is to continue on a traditional investing trajectory and provide strategic and tactical advice and support to high impact companies and organizations on nights and weekends through board service and ad-hoc advisory work (I would welcome ideas here as well!).

Investments

Codagenix

Alydia Health (acquired by Merck)

ARCH Vaccine StealthCo

EuBiologics (KOSDAQ IPO)

Janus Research (acquired by Lakeshore Cryonics

IanTech (acquired by Zeiss)

Codagenix

Endpoint Health

MDGH (PRV acquired by Novo

Fiberoptic Components

Curevo

Excision Biotherapeutics

Centivax

Adcole MAI (acquired by AE Partners